In Vivo to in Vitro to in Silico: Coping with Tidal Waves of Data at Biogen Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for In Vivo to in Vitro to in Silico: Coping with Tidal Waves of Data at Biogen case study

At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. In Vivo to in Vitro to in Silico: Coping with Tidal Waves of Data at Biogen case study is a Harvard Business School (HBR) case study written by Juan Enriquez, Gary P. Pisano, Gaye L. Bok. The In Vivo to in Vitro to in Silico: Coping with Tidal Waves of Data at Biogen (referred as “Biogen Mullen” from here on) case study provides evaluation & decision scenario in field of Technology & Operations. It also touches upon business topics such as - Value proposition, Research & development, Technology.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment

---

Case Description of In Vivo to in Vitro to in Silico: Coping with Tidal Waves of Data at Biogen Case Study

Biogen is a successful biotech company facing a critical juncture. CEO John Mullen ponders how technological changes introduced into the research function will shape larger corporate decisions. This world in which biotechnology companies operated had changed dramatically over the past few years. Parts of biology were rapidly evolving from being an individualistic, wet lab, bench-science driven field toward one where scientists manipulated huge amounts of data and divided up research steps into a factorylike production process. At the same time, the cost of developing a drug and bringing it to market had ballooned, from an estimated $231 million in 1991 to $802 million in 2000. Biogen was conservative in adopting new genomics tools. This case describes how the company decided to bring in house the latest genomics in silico tools and applied them to the discovery and research phase for drug development. The company also then restructured its research strategy. As the new tools and early-phase research began to bear fruit, Mullen realized that they implied significant changes down the road for other parts of Biogen.

Case Authors : Juan Enriquez, Gary P. Pisano, Gaye L. Bok

Topic : Technology & Operations

Related Areas : Research & development, Technology

---

Calculating Net Present Value (NPV) at 6% for In Vivo to in Vitro to in Silico: Coping with Tidal Waves of Data at Biogen Case Study

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 6 %	Discounted Cash Flows
Year 0	(10028609)	-10028609	-	-
Year 1	3456636	-6571973	3456636	0.9434	3260977
Year 2	3960639	-2611334	7417275	0.89	3524955
Year 3	3942462	1331128	11359737	0.8396	3310167
Year 4	3224399	4555527	14584136	0.7921	2554026
TOTAL			14584136		12650125

The Net Present Value at 6% discount rate is 2621516

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting

What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.

---

Capital Budgeting Approaches

Methods of Capital Budgeting

There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Payback Period
2. Internal Rate of Return
3. Net Present Value
4. Profitability Index

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Biogen Mullen shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.
2. Timing of the expected cash flows – stockholders of Biogen Mullen have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.

---

Formula and Steps to Calculate Net Present Value (NPV) of In Vivo to in Vitro to in Silico: Coping with Tidal Waves of Data at Biogen

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Technology & Operations Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Biogen Mullen often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Biogen Mullen needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 15 %	Discounted Cash Flows
Year 0	(10028609)	-10028609	-	-
Year 1	3456636	-6571973	3456636	0.8696	3005770
Year 2	3960639	-2611334	7417275	0.7561	2994812
Year 3	3942462	1331128	11359737	0.6575	2592233
Year 4	3224399	4555527	14584136	0.5718	1843561
TOTAL					10436376

The Net NPV after 4 years is 407767

(10436376 - 10028609 )

---

Calculating Net Present Value (NPV) at 20%

If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years	Cash Flow	Net Cash Flow	Cumulative     Cash Flow	Discount Rate @ 20 %	Discounted Cash Flows
Year 0	(10028609)	-10028609	-	-
Year 1	3456636	-6571973	3456636	0.8333	2880530
Year 2	3960639	-2611334	7417275	0.6944	2750444
Year 3	3942462	1331128	11359737	0.5787	2281517
Year 4	3224399	4555527	14584136	0.4823	1554976
TOTAL					9467467

The Net NPV after 4 years is -561142

At 20% discount rate the NPV is negative (9467467 - 10028609 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Biogen Mullen to discount cash flow at lower discount rates such as 15%.

Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Biogen Mullen has a NPV value higher than Zero then finance managers at Biogen Mullen can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Biogen Mullen, then the stock price of the Biogen Mullen should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Biogen Mullen should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

Understanding of risks involved in the project.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

What can impact the cash flow of the project.

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

What will be a multi year spillover effect of various taxation regulations.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.

---

Negotiation Strategy of In Vivo to in Vitro to in Silico: Coping with Tidal Waves of Data at Biogen

References & Further Readings

Juan Enriquez, Gary P. Pisano, Gaye L. Bok (2018), "In Vivo to in Vitro to in Silico: Coping with Tidal Waves of Data at Biogen Harvard Business Review Case Study. Published by HBR Publications.